Teva Pharmaceutical shares jump after results beat estimates
Teva shares surge 9% after its results
12 February 2020 - 22:08
Tel Aviv — Teva Pharmaceutical Industries said on Wednesday that a two-year restructuring has enabled the world’s largest generic drugmaker to turn a corner, as it reported slightly better than expected fourth-quarter results.
Its shares surged 9.1% in New York trade as the company also said it expected strong growth in two key drugs — new migraine drug Ajovy and Huntington’s treatment Austedo, in 2020 and expressed optimism over finalising a settlement in an opioid lawsuit in the US...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.